Monitoring low molecular weight heparins with antiXa activity: House of cards or firm foundation?

Hospital Pharmacy

Volumn 38, Issue 3, 2003, Pages 202-211

  Fraser, Gilles L ^a,b   McKenna, Joe P ^a  

^a MAINE MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; CREATININE; DALTEPARIN; DANAPAROID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; THROMBIN INHIBITOR; TINZAPARIN;

ACUTE HEART INFARCTION; ANTICOAGULATION; ARTIFICIAL KIDNEY; BLEEDING; BLEEDING TENDENCY; CATHETER; CLINICAL TRIAL; CREATININE CLEARANCE; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; OBESITY; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

EID: 0037343028     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870303800302     Document Type: Review

References (34)

1. Dalen JE, Hirsh J, eds. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 2001;119:1S-370.
2. Smith BS, Gandhi PJ. Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIa receptor antagonists in renal failure. J Thromb Thrombolysis. 2001;11:39-48.
3. Alhenc-Gelas M, Le Guenic J, Vitoux JF, et al. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Heamost. 1994;71:698-702.
4. Laposata M, Green D, Van Cott EM, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med. 1998;122:799-807.
5. Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Sem Thromb Hemost. 2001;27:519-22.
6. Vitt DE. Personal communication. Pharmion. November 14, 2002.
7. Heissler JE Personal communication. Pharmacia. September 25, 2001.
8. Greaves M, et al. Limitations of the laboratory monitoring of heparin therapy. Scientific and standardization committee communications: On behalf of the control of anticoagulation subcommittee of the scientific and standardization committee of the international society of thrombosis and haemostasis. Thromb Haemost. 2002;87:163-4.
9. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med. 2002;162:2605-9.
10. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 2001;21:218-34.
11. Huet Y, Janview G, Bendriss PH, et al. Treatment of established venous thromboembolism with enoxaparin: Preliminary report. Acta Chir Scand. 1990;556(suppl);116-20.
12. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment of proximal deep vein thrombosis. Arch Intern Med. 1993;153:1541-6.
13. Nieuwenhuis HK, Albada J, Banga JD, et al. Identification of risk factors for bleeding during treatment of acute VTE with heparin or low molecular weight heparin. Blood. 1991;78:2337-43.
14. Antman EM, et al. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol. 1997;29:1474-82.
15. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-elevation acute coronary syndromes. Am Heart J. 2002;143:753-9.
16. Kuijer P, Hutten B, Prins M, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457-620.
17. Pautas E, Gouin I, Bellot O, et al. Two hundred very elderly in-patients treated with tinzaparin administered once daily at standard curative dose [abstract]. The XVIIIth Congress of the International Society on Thrombosis and Haemostasis. Paris, France; July 2001.
18. Dorffler-Melly J, deJonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet. 2002;359:849-50.
19. Mayr AJ, Dunser M, Jochberger S, et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res. 2002;105:201-4.
20. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic insufficiency. Thromb Res. 1991;63:385-90.
21. Goudable C, Saivin S, Houin G, et al. Pharmacokinetics of low molecular weight heparin (Fraxaparine) in various stages of chronic renal failure. Nephron. 1991;59:543-5.
22. Brophy DF, Wazny LD, Gehr TWB, et al. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy. 2001;21:169-74.
23. Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency. Pharmacotherapy. 2000;20:771-5.
24. Collet JP, Montalescot G, Choussat R, et al. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol. 2001;80:81-2.
25. Polkinghorne KR, McMahon LP, Becker GJ. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis. 2002;40:990-5.
26. Leu JG, Chiang SS, Lin SM, et al. Low molecular weight heparin in hemodialysis patients with a bleeding tendency. Nephron. 2000;86;499-501.
27. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72:308-18.
28. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: A pharmacodynamic study. Thromb Haemost. 2002;87:817-23.
29. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001;134:191-202.
30. Rodie VA, Thomson AJ, Stewart FM, et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: A case series. BJOG. 2002;109:1020-4.
31. FDA. Medwatch-Lovenox letter. www.fda.gov.medwatch/SAFETY/2002/1ovenox.htm. Accessed May 30, 2002.
32. Groce JB, Vanscoy GJ, Gainor C. Anticoagulation bridging: Prosthetic heart valves, labeling changes, and limiting issues of liability. Formulary. 2002;37:473-5.
33. Tess Kilgour, Rockland, ME, 1999.
34. www.Enoxtest.com. Accessed November 30, 2002.